Log in
NYSE:BHVN

Biohaven Pharmaceutical Competitors

$89.62
-0.52 (-0.58 %)
(As of 11/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$89.19
Now: $89.62
$92.61
50-Day Range
$69.34
MA: $83.54
$98.24
52-Week Range
$26.56
Now: $89.62
$100.77
Volume656,568 shs
Average Volume790,481 shs
Market Capitalization$5.37 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.12

Competitors

Biohaven Pharmaceutical (NYSE:BHVN) Vs. RPRX, CTLT, HZNP, ELAN, ALNY, and BMRN

Should you be buying BHVN stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Biohaven Pharmaceutical, including Royalty Pharma (RPRX), Catalent (CTLT), Horizon Therapeutics Public (HZNP), Elanco Animal Health (ELAN), Alnylam Pharmaceuticals (ALNY), and BioMarin Pharmaceutical (BMRN).

Royalty Pharma (NASDAQ:RPRX) and Biohaven Pharmaceutical (NYSE:BHVN) are both finance companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Analyst Ratings

This is a summary of recent recommendations for Royalty Pharma and Biohaven Pharmaceutical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Royalty Pharma05402.44
Biohaven Pharmaceutical02902.82

Royalty Pharma currently has a consensus target price of $51.8750, suggesting a potential upside of 26.62%. Biohaven Pharmaceutical has a consensus target price of $84.20, suggesting a potential downside of 6.05%. Given Royalty Pharma's higher probable upside, research analysts plainly believe Royalty Pharma is more favorable than Biohaven Pharmaceutical.

Earnings and Valuation

This table compares Royalty Pharma and Biohaven Pharmaceutical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Royalty PharmaN/AN/AN/AN/AN/A
Biohaven PharmaceuticalN/AN/A$-528,800,000.00($10.91)-8.21

Profitability

This table compares Royalty Pharma and Biohaven Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Royalty PharmaN/AN/AN/A
Biohaven PharmaceuticalN/A-1,091.41%-120.85%

Institutional & Insider Ownership

36.4% of Royalty Pharma shares are held by institutional investors. Comparatively, 94.5% of Biohaven Pharmaceutical shares are held by institutional investors. 2.5% of Royalty Pharma shares are held by insiders. Comparatively, 19.1% of Biohaven Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Biohaven Pharmaceutical beats Royalty Pharma on 4 of the 7 factors compared between the two stocks.

Catalent (NYSE:CTLT) and Biohaven Pharmaceutical (NYSE:BHVN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, analyst recommendations, profitability, institutional ownership and risk.

Earnings & Valuation

This table compares Catalent and Biohaven Pharmaceutical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Catalent$3.09 billion5.04$173 million$1.8850.35
Biohaven PharmaceuticalN/AN/A$-528,800,000.00($10.91)-8.21

Catalent has higher revenue and earnings than Biohaven Pharmaceutical. Biohaven Pharmaceutical is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for Catalent and Biohaven Pharmaceutical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Catalent01702.88
Biohaven Pharmaceutical02902.82

Catalent currently has a consensus target price of $105.50, indicating a potential upside of 11.46%. Biohaven Pharmaceutical has a consensus target price of $84.20, indicating a potential downside of 6.05%. Given Catalent's stronger consensus rating and higher probable upside, equities analysts clearly believe Catalent is more favorable than Biohaven Pharmaceutical.

Volatility and Risk

Catalent has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500. Comparatively, Biohaven Pharmaceutical has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.

Profitability

This table compares Catalent and Biohaven Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Catalent9.25%14.20%4.83%
Biohaven PharmaceuticalN/A-1,091.41%-120.85%

Insider and Institutional Ownership

91.0% of Catalent shares are held by institutional investors. Comparatively, 94.5% of Biohaven Pharmaceutical shares are held by institutional investors. 1.0% of Catalent shares are held by company insiders. Comparatively, 19.1% of Biohaven Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Catalent beats Biohaven Pharmaceutical on 10 of the 13 factors compared between the two stocks.

Biohaven Pharmaceutical (NYSE:BHVN) and Horizon Therapeutics Public (NASDAQ:HZNP) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk and profitability.

Profitability

This table compares Biohaven Pharmaceutical and Horizon Therapeutics Public's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biohaven PharmaceuticalN/A-1,091.41%-120.85%
Horizon Therapeutics Public43.55%25.66%14.19%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Biohaven Pharmaceutical and Horizon Therapeutics Public, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biohaven Pharmaceutical02902.82
Horizon Therapeutics Public011002.91

Biohaven Pharmaceutical presently has a consensus price target of $84.20, suggesting a potential downside of 6.05%. Horizon Therapeutics Public has a consensus price target of $81.1667, suggesting a potential upside of 17.80%. Given Horizon Therapeutics Public's stronger consensus rating and higher possible upside, analysts clearly believe Horizon Therapeutics Public is more favorable than Biohaven Pharmaceutical.

Insider & Institutional Ownership

94.5% of Biohaven Pharmaceutical shares are held by institutional investors. Comparatively, 89.2% of Horizon Therapeutics Public shares are held by institutional investors. 19.1% of Biohaven Pharmaceutical shares are held by company insiders. Comparatively, 4.3% of Horizon Therapeutics Public shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Biohaven Pharmaceutical has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500. Comparatively, Horizon Therapeutics Public has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500.

Earnings & Valuation

This table compares Biohaven Pharmaceutical and Horizon Therapeutics Public's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biohaven PharmaceuticalN/AN/A$-528,800,000.00($10.91)-8.21
Horizon Therapeutics Public$1.30 billion11.70$573.02 million$1.9435.52

Horizon Therapeutics Public has higher revenue and earnings than Biohaven Pharmaceutical. Biohaven Pharmaceutical is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Summary

Horizon Therapeutics Public beats Biohaven Pharmaceutical on 11 of the 13 factors compared between the two stocks.

Elanco Animal Health (NYSE:ELAN) and Biohaven Pharmaceutical (NYSE:BHVN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Profitability

This table compares Elanco Animal Health and Biohaven Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Elanco Animal Health-8.45%3.43%2.04%
Biohaven PharmaceuticalN/A-1,091.41%-120.85%

Analyst Ratings

This is a breakdown of current ratings for Elanco Animal Health and Biohaven Pharmaceutical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Elanco Animal Health22702.45
Biohaven Pharmaceutical02902.82

Elanco Animal Health presently has a consensus price target of $29.2778, suggesting a potential downside of 7.87%. Biohaven Pharmaceutical has a consensus price target of $84.20, suggesting a potential downside of 6.05%. Given Biohaven Pharmaceutical's stronger consensus rating and higher possible upside, analysts plainly believe Biohaven Pharmaceutical is more favorable than Elanco Animal Health.

Valuation and Earnings

This table compares Elanco Animal Health and Biohaven Pharmaceutical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elanco Animal Health$3.07 billion4.88$67.90 million$1.0629.98
Biohaven PharmaceuticalN/AN/A$-528,800,000.00($10.91)-8.21

Elanco Animal Health has higher revenue and earnings than Biohaven Pharmaceutical. Biohaven Pharmaceutical is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Elanco Animal Health has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, Biohaven Pharmaceutical has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.

Insider and Institutional Ownership

75.9% of Elanco Animal Health shares are held by institutional investors. Comparatively, 94.5% of Biohaven Pharmaceutical shares are held by institutional investors. 0.1% of Elanco Animal Health shares are held by company insiders. Comparatively, 19.1% of Biohaven Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Biohaven Pharmaceutical beats Elanco Animal Health on 8 of the 13 factors compared between the two stocks.

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Biohaven Pharmaceutical (NYSE:BHVN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Volatility and Risk

Alnylam Pharmaceuticals has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. Comparatively, Biohaven Pharmaceutical has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Alnylam Pharmaceuticals and Biohaven Pharmaceutical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alnylam Pharmaceuticals161302.60
Biohaven Pharmaceutical02902.82

Alnylam Pharmaceuticals currently has a consensus price target of $153.00, suggesting a potential upside of 21.96%. Biohaven Pharmaceutical has a consensus price target of $84.20, suggesting a potential downside of 6.05%. Given Alnylam Pharmaceuticals' higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Biohaven Pharmaceutical.

Earnings & Valuation

This table compares Alnylam Pharmaceuticals and Biohaven Pharmaceutical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alnylam Pharmaceuticals$219.75 million66.32$-886,120,000.00($8.11)-15.47
Biohaven PharmaceuticalN/AN/A$-528,800,000.00($10.91)-8.21

Biohaven Pharmaceutical has lower revenue, but higher earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Biohaven Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

83.3% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.5% of Biohaven Pharmaceutical shares are owned by institutional investors. 3.5% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 19.1% of Biohaven Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Alnylam Pharmaceuticals and Biohaven Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alnylam Pharmaceuticals-222.19%-65.96%-31.38%
Biohaven PharmaceuticalN/A-1,091.41%-120.85%

Summary

Alnylam Pharmaceuticals beats Biohaven Pharmaceutical on 7 of the 13 factors compared between the two stocks.

BioMarin Pharmaceutical (NASDAQ:BMRN) and Biohaven Pharmaceutical (NYSE:BHVN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, risk, dividends and valuation.

Insider and Institutional Ownership

89.4% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 94.5% of Biohaven Pharmaceutical shares are held by institutional investors. 2.2% of BioMarin Pharmaceutical shares are held by insiders. Comparatively, 19.1% of Biohaven Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for BioMarin Pharmaceutical and Biohaven Pharmaceutical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioMarin Pharmaceutical0101302.57
Biohaven Pharmaceutical02902.82

BioMarin Pharmaceutical currently has a consensus price target of $119.6667, indicating a potential upside of 53.12%. Biohaven Pharmaceutical has a consensus price target of $84.20, indicating a potential downside of 6.05%. Given BioMarin Pharmaceutical's higher possible upside, equities analysts plainly believe BioMarin Pharmaceutical is more favorable than Biohaven Pharmaceutical.

Profitability

This table compares BioMarin Pharmaceutical and Biohaven Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioMarin Pharmaceutical45.74%4.34%2.84%
Biohaven PharmaceuticalN/A-1,091.41%-120.85%

Earnings & Valuation

This table compares BioMarin Pharmaceutical and Biohaven Pharmaceutical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioMarin Pharmaceutical$1.70 billion8.33$-23,850,000.00$0.071,116.43
Biohaven PharmaceuticalN/AN/A$-528,800,000.00($10.91)-8.21

BioMarin Pharmaceutical has higher revenue and earnings than Biohaven Pharmaceutical. Biohaven Pharmaceutical is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

BioMarin Pharmaceutical has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Biohaven Pharmaceutical has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.

Summary

BioMarin Pharmaceutical beats Biohaven Pharmaceutical on 9 of the 13 factors compared between the two stocks.


Biohaven Pharmaceutical Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Royalty Pharma logo
RPRX
Royalty Pharma
1.8$40.97-3.4%$15.90 billionN/A0.00
Catalent logo
CTLT
Catalent
1.9$94.65-0.0%$15.59 billion$3.09 billion60.29
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.2$68.90-0.2%$15.21 billion$1.30 billion18.83Analyst Downgrade
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.9$31.78-0.5%$15.00 billion$3.07 billion-55.75Analyst Report
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$125.45-0.2%$14.57 billion$219.75 million-16.02Analyst Report
Analyst Revision
Heavy News Reporting
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.0$78.15-0.2%$14.19 billion$1.70 billion17.88
Grifols logo
GRFS
Grifols
1.5$18.21-1.0%$12.52 billion$5.71 billion20.23
MyoKardia logo
MYOK
MyoKardia
0.9$224.91-0.0%$11.99 billion$33.56 million-39.88
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.0$225.46-0.9%$11.34 billion$3.34 million-29.28
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
2.0$135.72-0.4%$10.71 billion$380.83 million-19.33
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.4$64.33-1.9%$10.66 billion$2.32 billion42.32
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
2.0$9.75-1.1%$10.65 billion$16.89 billion4.22Analyst Report
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.4$55.86-2.0%$8.88 billion$339.08 million-32.48
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.8$162.15-1.8%$8.66 billion$14.98 million-19.75
Mylan logo
MYL
Mylan
1.8$15.86-0.0%$8.59 billion$11.50 billion29.92High Trading Volume
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$141.83-0.7%$7.90 billion$2.16 billion44.74
Galapagos logo
GLPG
Galapagos
1.3$120.78-2.3%$7.89 billion$1.00 billion-18.30Analyst Report
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.3$119.83-0.8%$7.32 billion$103.71 million-22.96Analyst Report
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.8$50.24-0.4%$7.02 billion$1.12 billion104.67Insider Selling
Unusual Options Activity
Bausch Health Companies logo
BHC
Bausch Health Companies
1.7$19.17-0.4%$6.81 billion$8.60 billion-3.52
Perrigo logo
PRGO
Perrigo
2.4$47.93-1.0%$6.54 billion$4.84 billion27.55
Zai Lab logo
ZLAB
Zai Lab
1.2$106.69-0.3%$6.20 billion$12.98 million-35.21
United Therapeutics logo
UTHR
United Therapeutics
1.4$135.07-0.3%$6.00 billion$1.45 billion13.87
BBIO
BridgeBio Pharma
1.4$48.47-3.1%$5.94 billion$40.56 million-14.21
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.2$22.76-1.0%$5.93 billion$182.24 million-19.79
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.9$105.32-1.9%$5.87 billion$66.51 million19.43
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.6$57.02-5.9%$5.83 billion$168.80 million-228.08Earnings Announcement
Analyst Report
Analyst Revision
Heavy News Reporting
Allakos logo
ALLK
Allakos
1.0$103.73-1.4%$5.45 billionN/A-37.86
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.6$151.89-8.3%$5.15 billion$26.52 million-14.16Analyst Upgrade
TPTX
Turning Point Therapeutics
1.7$106.05-1.4%$5.11 billionN/A-28.51
SDGR
Schrödinger
1.7$63.60-4.1%$4.42 billion$85.54 million0.00Analyst Upgrade
Insider Selling
Unusual Options Activity
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.1$63.53-0.6%$4.34 billion$306.98 million-9.05
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.2$82.70-3.4%$4.30 billion$6.87 million-7.01
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$80.41-1.5%$4.26 billion$1.11 billion25.86
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$31.06-0.1%$4.14 billion$204.89 million-38.83
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.7$127.61-1.3%$3.96 billion$311.33 million-74.19Insider Selling
Insmed logo
INSM
Insmed
1.1$38.58-3.0%$3.93 billion$136.47 million-14.84Analyst Report
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$29.49-0.4%$3.88 billion$150,000.00-14.18
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.50-0.2%$3.81 billion$806.43 million-9.28
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$54.00-3.6%$3.74 billion$36.13 million-80.60
FibroGen logo
FGEN
FibroGen
1.6$40.02-3.3%$3.64 billion$256.58 million-15.33Analyst Downgrade
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.5$47.46-0.3%$3.59 billionN/A-6.40Analyst Report
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.4$61.80-0.1%$3.52 billion$25 million-12.36Analyst Revision
Eidos Therapeutics logo
EIDX
Eidos Therapeutics
1.2$88.71-3.0%$3.43 billion$26.69 million-33.48
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.8$45.66-0.7%$3.16 billion$117.91 million-9.26Analyst Revision
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.7$16.48-1.3%$2.96 billion$114.62 million-6.65Insider Selling
Alkermes logo
ALKS
Alkermes
1.3$18.43-0.3%$2.93 billion$1.17 billion-40.06
Pacira BioSciences logo
PCRX
Pacira BioSciences
1.2$63.36-1.5%$2.75 billion$421.03 million-253.44
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$73.42-1.5%$2.74 billionN/A-27.29
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.6$43.85-0.6%$2.71 billion$2.11 million-9.49
This page was last updated on 11/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.